Longaevus Technologies

Age-Related Inflammation

Inflammation and Aging: How to Turn Back the Clock


As we age, chronic inflammation becomes more prevalent in our cells, leading to various diseases like psoriasis, rheumatoid arthritis, and cancer. Addressing this issue, Longaevus conducted extensive research, screening over 700 genes in search of genetic solutions. Our ground-breaking findings have revealed that reducing the activity of LONG-001 and LONG-002 have a remarkable rejuvenating effect on human cells by suppressing the inflammation cascade.

With this promising discovery, Longaevus is committed to presenting potential leads for this target in the upcoming year. Our goal is to develop innovative therapies that cater to unmet clinical needs, particularly in treating conditions like psoriasis and rheumatoid arthritis. By harnessing the power of LONG-001 and LONG-002, we aspire to bring new hope to individuals suffering from these debilitating diseases and significantly improve their quality of life.



The intricate mechanism of chronic inflammation in aging cells involves a multifaceted interplay of factors, including DNA damage, accumulation of senescent cells, and compromised immune function. These alterations create an immune system imbalance and trigger the release of pro-inflammatory molecules, leading to tissue damage and disease. To combat this complex issue, researchers are exploring various strategies like anti-inflammatory drugs and other interventions. However, existing solutions often focus on the final stages of the inflammatory cascade and may not effectively prevent all pathogenic processes involved in chronic inflammation.

At Longaevus, we take a different approach in addressing chronic inflammation associated with aging. Instead of targeting individual pathways, we identify and screen for specific genes that become overactivated during the pathological inflammatory process. By homing in on these activated genes, we tackle the entire pathologic inflammatory cascade simultaneously. This comprehensive method allows us to provide a more effective solution, targeting multiple pathways in unison, to counteract chronic inflammation associated with aging. Through our innovative approach, we aim to bring forth ground-breaking solutions that hold the potential to significantly improve the lives of individuals suffering from age-related inflammatory diseases.

Our Approach:

In our research, we utilized a combination of primary skin fibroblasts obtained from various elderly patients. Our investigation extended beyond solely examining inflammation; we also measured multiple markers to assess various changes and cell viability readouts. To inhibit the target genes, we employed lentiviral shRNA, which allowed us to observe the effects more effectively.

As a result of these experiments, our company successfully identified a remarkable rejuvenating effect on human cells when we reduced the activity of two crucial genes, namely LONG-001 and LONG-002. These genes play a pivotal role in suppressing inflammation caused by the accumulation of DNA damage associated with aging. Moreover, our findings indicate that targeting LONG-001 and LONG-002 has the potential to reverse multiple aging phenotypes, offering exciting possibilities for age-related conditions.

We are dedicated to leveraging the knowledge gained from these discoveries to provide effective solutions for chronic inflammation and to enhance the overall quality of life for individuals affected by age-related diseases. By focusing on these specific genes, we aim to pave the way for innovative therapies that have the potential to bring transformative benefits to patients suffering from age-related ailments.

Our Approach

Our Team

Francesca Lugarini

Francesca Lugarini, PhD


Francesca is a Biochemist and Biomedical Scientist, with a strong passion for aging pathways and aging-associated diseases. At Longaevus Technologies, Francesca leads the largest project of the company focused on 50 potential targets.

Alexey Moskalev

Alexey Moskalev, PhD


Alexey spent over 20 years studying mechanisms of aging, longevity, and stress, including DNA repair, heat shock proteins, NF-kB, TOR- and PI3K-signaling cascade, and apoptosis. Dr. Moskalev works as a scientific director at Longaevus.

Dmitry Klokov

Dmitry Klokov, PhD


Dmitry leads a Radiotoxicology research laboratory at the Institute of Radioprotection and Nuclear Safety in Paris. At Longaevus Technologies, Dmitry contributes as CSO to the largest project of the company focused on 50 potential targets.

Ivan Morgunov

Ivan Morgunov


Ivan leads Longaevus Technologies in its mission to explore new and diverse pathways to healthy longevity with longer lifespan and fewer chronic diseases.

Viktor Korolchuk

Viktor Korolchuk, PhD

Molecular Biologist and Member of British Society for Research on Ageing, Scientific Advisor

Dr. Viktor Korolchuk is a Scientific Advisory board member at Longaevus Technologies. He assists in developing Longaevus’s pipeline and adds his experience and perspectives to scientific discussions.

Sherif Idriss

Sherif Idriss, PhD


Managing Director-Founder of Lübeck Consulting Group. At Longaevus Technologies, Sherif contributes as CEO to one of the most advanced projects within Longaevus.

Rakhan Aimbetov

Rakhan Aimbetov, PhD

Advanced Analyst

Rakhan is a cell and molecular biologist with expertise in epigenetics and aging. Currently, Rakhan works as an advanced genetic analyst at Longaevus, bringing his undeniable expertise and international experience.

Faya Movchan

Faya Movchan

Lab Manager and Computational Neuroscientist

Laboratory Manager, contributes as Project Assistant, and oversees the role of Software Manager.


Longaevus Technologies

Get in touch